December 19 2018, David R Brown
Azelis increases its pharma presence in Italy through the acquisition of Deafarma S.r.l.
Azelis has announced that it has entered into exclusive discussion to acquire 100% of the outstanding shares in Deafarma Srl., an Italian distributor of active pharmaceutical ingredients (APIs). In addition to distribution of API's, Deafarma supports its customers with a wide range of services, such as the search for new API's, regulatory affairs assistance and new pharmaceutical dossier support. The transaction is is expected to be completed in the first quarter of 2019.
There is an excellent strategic fit that supports our further growth in the region, allowing us to provide an improved product offering and customer reachMarco Gerosa
Regional Managing Director Azelis Italy
Marco Gerosa, Regional Managing Director Italy, commented, “Deafarma has an excellent reputation in the market and we are delighted to welcome them to Azelis. Mrs. Gorla and Mr. Minin have established a strong relationship with their customers and principals. The company is known for the flexibility they offer to customers, high service levels, quick feedback, exemplary regulatory support and assistance for new pharmaceutical dossier development.”
Mrs. Natalia Gorla and Mr. Leonardo Minin, Founders and Managing Directors of Deafarma, added, “We have always had the high quality service to customers at the heart of our business. Joining Azelis will enable us to focus more on business development whilst leveraging Azelis’ global network. This will be beneficial for us and all our business partners and will open up new growth opportunities on both sides.”
All Deafarma employees will be joining the Azelis team, including both founders, who started the company in 1998.
Azelis also noted that the acquisition illustrates the support provided by owner EQT since it took over the Belgium-based distributor together with PSP Investments earlier this year. The two funds revealed in June 2018 they were in exclusive negotiations to take over Azelis from private equity owner Apax Partners. EQT is confident that the expanded range of services and global reach provided by this acquisition will continue to bring benefits to customers and principals of the combined group.
Azelis is a leading global speciality chemicals and food ingredients distributor providing a diverse range of innovative products and services. Dedicated teams serve customers in the following industries: Personal Care, Pharma, Food & Health, Animal Nutrition, Specialty Agri/Horti, Homecare & Industrial Cleaning, CASE (coatings, adhesives, sealants & elastomers), Chemicals, Lubricants & Metal Working Fluids and Rubber & Plastic Additives. The Group has a turnover of around EUR 1.8 billion and employs around 1,800 people located in more than 60 facilities in over 40 countries across the EMEA, Asia Pacific and Americas regions.
Source(s): Azelis Press Release